Literature DB >> 15987677

p300/CBP-associated factor drives DEK into interchromatin granule clusters.

Joanne Cleary1, Kajal V Sitwala, Michael S Khodadoust, Roland P S Kwok, Nirit Mor-Vaknin, Marek Cebrat, Philip A Cole, David M Markovitz.   

Abstract

DEK is a mammalian protein that has been implicated in the pathogenesis of autoimmune diseases and cancer, including acute myeloid leukemia, melanoma, glioblastoma, hepatocellular carcinoma, and bladder cancer. In addition, DEK appears to participate in multiple cellular processes, including transcriptional repression, mRNA processing, and chromatin remodeling. Sub-nuclear distribution of this protein, with the attendant functional ramifications, has remained a controversial topic. Here we report that DEK undergoes acetylation in vivo at lysine residues within the first 70 N-terminal amino acids. Acetylation of DEK decreases its affinity for DNA elements within the promoter, which is consistent with the involvement of DEK in transcriptional repression. Furthermore, deacetylase inhibition results in accumulation of DEK within interchromatin granule clusters (IGCs), sub-nuclear structures that contain RNA processing factors. Overexpression of P/CAF acetylase drives DEK into IGCs, and addition of a newly developed, synthetic, cell-permeable P/CAF inhibitor blocks this movement. To our knowledge, this is the first reported example of acetylation playing a direct role in relocation of a protein to IGCs, and this may explain how DEK can function in multiple pathways that take place in distinct sub-nuclear compartments. These findings also suggest that DEK-associated malignancies and autoimmune diseases might be amenable to treatment with agents that alter acetylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15987677     DOI: 10.1074/jbc.M500884200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

2.  The DEK nuclear autoantigen is a secreted chemotactic factor.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; Neil Faulkner; Maureen Legendre; Michael S Khodadoust; Ferdinand Kappes; Jeffrey H Ruth; Alisa Koch; David Glass; Lilli Petruzzelli; Barbara S Adams; David M Markovitz
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

3.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.

Authors:  Nirit Mor-Vaknin; Ferdinand Kappes; Amalie E Dick; Maureen Legendre; Catalina Damoc; Seagal Teitz-Tennenbaum; Roland Kwok; Elisa Ferrando-May; Barbara S Adams; David M Markovitz
Journal:  Arthritis Rheum       Date:  2011-02

4.  Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation.

Authors:  Andreas N Kuhn; Maria A van Santen; Andreas Schwienhorst; Henning Urlaub; Reinhard Lührmann
Journal:  RNA       Date:  2008-11-24       Impact factor: 4.942

Review 5.  Chemical probes for histone-modifying enzymes.

Authors:  Philip A Cole
Journal:  Nat Chem Biol       Date:  2008-10       Impact factor: 15.040

6.  Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.

Authors:  Maroun Karam; Morgan Thenoz; Valérie Capraro; Jean-Philippe Robin; Christiane Pinatel; Agnès Lancon; Perrine Galia; David Sibon; Xavier Thomas; Sophie Ducastelle-Lepretre; Franck Nicolini; Mohamed El-Hamri; Youcef Chelghoun; Eric Wattel; Franck Mortreux
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

Review 7.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

8.  Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.

Authors:  Trisha M Wise-Draper; Hillary V Allen; Elizabeth E Jones; Kristen B Habash; Hiroshi Matsuo; Susanne I Wells
Journal:  Mol Cell Biol       Date:  2006-08-07       Impact factor: 4.272

9.  DEK regulates hematopoietic stem engraftment and progenitor cell proliferation.

Authors:  Hal E Broxmeyer; Ferdinand Kappes; Nirit Mor-Vaknin; Maureen Legendre; John Kinzfogl; Scott Cooper; Giao Hangoc; David M Markovitz
Journal:  Stem Cells Dev       Date:  2011-10-27       Impact factor: 3.272

Review 10.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.